Home /
Chemotherapy – Washington University School of Medicine -Treatment Details
|
|
| Description: |
| Patients: This Phase II study involved 43 patients with advanced mesothelioma. Thirty-nine patients were men and four were women. The median age was 72 years.
Treatment: The treatment consisted of one chemotherapeutic agent: gefitinib. Toxicity: One patient died during this study of respiratory failure. Grade 3-4 toxicities included dehydration, diarrhea, nausea, and vomiting. Results: The median overall survival was 6.8 months. Twenty-four patients responded to treatment (1 complete response, 1 partial response). However, the authors concluded, “gefitinib was not active in malignant mesothelioma.” Correspondence: Ramaswamy Govindan |
“My Name is Paul Kraus and I Have Survived Mesothelioma for Over 20 Years.”
In 1997 I was diagnosed with mesothelioma. The doctors gave me just a few short months to live...
But here I am, 20 years later, alive and well.
I wrote a book explaining how I became the longest living mesothelioma survivor in the world.
Today, I'd like to give you a copy for free because I want more people to survive this disease.
All you have to do is click the button below now. You will receive the book within 72 hours.
I wish you good health.
Sincerely,
"It has been over four years now and I can honestly say I am doing great. I highly recommend this book because it is inspirational and educational."